Vadastuximab talirine: Additional Phase I data

Data from 49 evaluable newly diagnosed patients with CD33-positive AML in an open-label, U.S. Phase I trial showed that IV

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE